+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Africa HIV Treatment Drugs Market 2023-2027

  • PDF Icon

    Report

  • 120 Pages
  • November 2022
  • Region: Africa
  • TechNavio
  • ID: 5692420
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The HIV treatment drugs market in Africa and it is poised to grow by $321.6 million during 2023-2027, accelerating at a CAGR of 3.76% during the forecast period. The market is driven by the increasing prevalence of STDs, favorable international programs, and government collaborations.

This report on the HIV treatment drugs market in Africa provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.

The HIV treatment drugs market in Africa is segmented as below:

By Drug Class

  • Reverse transcriptase inhibitors
  • Protease inhibitors
  • Integrase inhibitors
  • Fusion inhibitors
  • Coreceptor antagonists

By Route of Administration

  • Oral drugs
  • Injectable drugs

By Geography

  • South Africa
  • Nigeria
  • Kenya
  • Uganda
  • Rest of Africa
This study identifies the increase in awareness by various organizations as one of the prime reasons driving the HIV treatment drugs market growth in Africa during the next few years. Also, the growing focus on elimination of mother-to-child transmission of HIV and high HIV drug resistance will lead to sizable demand in the market.

The report on HIV treatment drugs market in Africa covers the following areas:

  • HIV treatment drugs market sizing
  • HIV treatment drugs market forecast
  • HIV treatment drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HIV treatment drugs market vendors that include Abbott Laboratories, AbbVie Inc., Alpha Pharma, Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Avacare Health, Boehringer Ingelheim International GmbH, Cipla Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson, Merck and Co. Inc., SSI Diagnostica AS, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Theratechnologies Inc., and Viatris Inc. Also, the HIV treatment drugs market in Africa analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The analyst's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Country Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Africa - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Regional - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Africa: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Regional - Market size and forecast 2022-2027 ($ million)
4 Historic Market Size
4.1 HIV treatment drugs market in Africa 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on HIV treatment drugs market in Africa 2017 - 2021 ($ million)
4.2 Drug Class Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million)
4.3 Route Of Administration Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Route Of Administration Segment 2017 - 2021 ($ million)
4.4 Country Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 22: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 23: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 24: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 25: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 26: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 27: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 28: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Drug Class
6.1 Market segments
Exhibit 29: Chart on Drug Class - Market share 2022-2027 (%)
Exhibit 30: Data Table on Drug Class - Market share 2022-2027 (%)
6.2 Comparison by Drug Class
Exhibit 31: Chart on Comparison by Drug Class
Exhibit 32: Data Table on Comparison by Drug Class
6.3 Reverse transcriptase inhibitors - Market size and forecast 2022-2027
Exhibit 33: Chart on Reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 34: Data Table on Reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Chart on Reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 36: Data Table on Reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
6.4 Protease inhibitors - Market size and forecast 2022-2027
Exhibit 37: Chart on Protease inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 38: Data Table on Protease inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Chart on Protease inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 40: Data Table on Protease inhibitors - Year-over-year growth 2022-2027 (%)
6.5 Integrase inhibitors - Market size and forecast 2022-2027
Exhibit 41: Chart on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 42: Data Table on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Chart on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 44: Data Table on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
6.6 Fusion inhibitors - Market size and forecast 2022-2027
Exhibit 45: Chart on Fusion inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 46: Data Table on Fusion inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibit 47: Chart on Fusion inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 48: Data Table on Fusion inhibitors - Year-over-year growth 2022-2027 (%)
6.7 Coreceptor antagonists - Market size and forecast 2022-2027
Exhibit 49: Chart on Coreceptor antagonists - Market size and forecast 2022-2027 ($ million)
Exhibit 50: Data Table on Coreceptor antagonists - Market size and forecast 2022-2027 ($ million)
Exhibit 51: Chart on Coreceptor antagonists - Year-over-year growth 2022-2027 (%)
Exhibit 52: Data Table on Coreceptor antagonists - Year-over-year growth 2022-2027 (%)
6.8 Market opportunity by Drug Class
Exhibit 53: Market opportunity by Drug Class ($ million)
7 Market Segmentation by Route of Administration
7.1 Market segments
Exhibit 54: Chart on Route of Administration - Market share 2022-2027 (%)
Exhibit 55: Data Table on Route of Administration - Market share 2022-2027 (%)
7.2 Comparison by Route of Administration
Exhibit 56: Chart on Comparison by Route of Administration
Exhibit 57: Data Table on Comparison by Route of Administration
7.3 Oral drugs - Market size and forecast 2022-2027
Exhibit 58: Chart on Oral drugs - Market size and forecast 2022-2027 ($ million)
Exhibit 59: Data Table on Oral drugs - Market size and forecast 2022-2027 ($ million)
Exhibit 60: Chart on Oral drugs - Year-over-year growth 2022-2027 (%)
Exhibit 61: Data Table on Oral drugs - Year-over-year growth 2022-2027 (%)
7.4 Injectable drugs - Market size and forecast 2022-2027
Exhibit 62: Chart on Injectable drugs - Market size and forecast 2022-2027 ($ million)
Exhibit 63: Data Table on Injectable drugs - Market size and forecast 2022-2027 ($ million)
Exhibit 64: Chart on Injectable drugs - Year-over-year growth 2022-2027 (%)
Exhibit 65: Data Table on Injectable drugs - Year-over-year growth 2022-2027 (%)
7.5 Market opportunity by Route of Administration
Exhibit 66: Market opportunity by Route of Administration ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 67: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 68: Chart on Market share by geography - 2022-2027 (%)
Exhibit 69: Data Table on Market share by geography - 2022-2027 (%)
9.2 Geographic comparison
Exhibit 70: Chart on Geographic comparison
Exhibit 71: Data Table on Geographic comparison
9.3 South Africa - Market size and forecast 2022-2027
Exhibit 72: Chart on South Africa - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Data Table on South Africa - Market size and forecast 2022-2027 ($ million)
Exhibit 74: Chart on South Africa - Year-over-year growth 2022-2027 (%)
Exhibit 75: Data Table on South Africa - Year-over-year growth 2022-2027 (%)
9.4 Nigeria - Market size and forecast 2022-2027
Exhibit 76: Chart on Nigeria - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Data Table on Nigeria - Market size and forecast 2022-2027 ($ million)
Exhibit 78: Chart on Nigeria - Year-over-year growth 2022-2027 (%)
Exhibit 79: Data Table on Nigeria - Year-over-year growth 2022-2027 (%)
9.5 Kenya - Market size and forecast 2022-2027
Exhibit 80: Chart on Kenya - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Data Table on Kenya - Market size and forecast 2022-2027 ($ million)
Exhibit 82: Chart on Kenya - Year-over-year growth 2022-2027 (%)
Exhibit 83: Data Table on Kenya - Year-over-year growth 2022-2027 (%)
9.6 Uganda - Market size and forecast 2022-2027
Exhibit 84: Chart on Uganda - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Data Table on Uganda - Market size and forecast 2022-2027 ($ million)
Exhibit 86: Chart on Uganda - Year-over-year growth 2022-2027 (%)
Exhibit 87: Data Table on Uganda - Year-over-year growth 2022-2027 (%)
9.7 Rest of Africa - Market size and forecast 2022-2027
Exhibit 88: Chart on Rest of Africa - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Data Table on Rest of Africa - Market size and forecast 2022-2027 ($ million)
Exhibit 90: Chart on Rest of Africa - Year-over-year growth 2022-2027 (%)
Exhibit 91: Data Table on Rest of Africa - Year-over-year growth 2022-2027 (%)
9.8 Market opportunity by geography
Exhibit 92: Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 93: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 94: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 95: Overview on factors of disruption
11.4 Industry risks
Exhibit 96: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 97: Vendors covered
12.2 Market positioning of vendors
Exhibit 98: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 99: Abbott Laboratories - Overview
Exhibit 100: Abbott Laboratories - Business segments
Exhibit 101: Abbott Laboratories - Key news
Exhibit 102: Abbott Laboratories - Key offerings
Exhibit 103: Abbott Laboratories - Segment focus
12.4 AbbVie Inc.
Exhibit 104: AbbVie Inc. - Overview
Exhibit 105: AbbVie Inc. - Product / Service
Exhibit 106: AbbVie Inc. - Key offerings
12.5 Alpha Pharma
Exhibit 107: Alpha Pharma - Overview
Exhibit 108: Alpha Pharma - Product / Service
Exhibit 109: Alpha Pharma - Key offerings
12.6 Aspen Pharmacare Holdings Ltd.
Exhibit 110: Aspen Pharmacare Holdings Ltd. - Overview
Exhibit 111: Aspen Pharmacare Holdings Ltd. - Business segments
Exhibit 112: Aspen Pharmacare Holdings Ltd. - Key offerings
Exhibit 113: Aspen Pharmacare Holdings Ltd. - Segment focus
12.7 AstraZeneca Plc
Exhibit 114: AstraZeneca Plc - Overview
Exhibit 115: AstraZeneca Plc - Product / Service
Exhibit 116: AstraZeneca Plc - Key news
Exhibit 117: AstraZeneca Plc - Key offerings
12.8 Aurobindo Pharma Ltd.
Exhibit 118: Aurobindo Pharma Ltd. - Overview
Exhibit 119: Aurobindo Pharma Ltd. - Product / Service
Exhibit 120: Aurobindo Pharma Ltd. - Key offerings
12.9 Avacare Health
Exhibit 121: Avacare Health - Overview
Exhibit 122: Avacare Health - Product / Service
Exhibit 123: Avacare Health - Key offerings
12.10 Cipla Ltd.
Exhibit 124: Cipla Ltd. - Overview
Exhibit 125: Cipla Ltd. - Business segments
Exhibit 126: Cipla Ltd. - Key news
Exhibit 127: Cipla Ltd. - Key offerings
Exhibit 128: Cipla Ltd. - Segment focus
12.11 F. Hoffmann La Roche Ltd.
Exhibit 129: F. Hoffmann La Roche Ltd. - Overview
Exhibit 130: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 131: F. Hoffmann La Roche Ltd. - Key news
Exhibit 132: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 133: F. Hoffmann La Roche Ltd. - Segment focus
12.12 Gilead Sciences Inc.
Exhibit 134: Gilead Sciences Inc. - Overview
Exhibit 135: Gilead Sciences Inc. - Product / Service
Exhibit 136: Gilead Sciences Inc. - Key news
Exhibit 137: Gilead Sciences Inc. - Key offerings
12.13 GlaxoSmithKline Plc
Exhibit 138: GlaxoSmithKline Plc - Overview
Exhibit 139: GlaxoSmithKline Plc - Business segments
Exhibit 140: GlaxoSmithKline Plc - Key offerings
Exhibit 141: GlaxoSmithKline Plc - Segment focus
12.14 Merck and Co. Inc.
Exhibit 142: Merck and Co. Inc. - Overview
Exhibit 143: Merck and Co. Inc. - Business segments
Exhibit 144: Merck and Co. Inc. - Key news
Exhibit 145: Merck and Co. Inc. - Key offerings
Exhibit 146: Merck and Co. Inc. - Segment focus
12.15 Sun Pharmaceutical Industries Ltd.
Exhibit 147: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 148: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 149: Sun Pharmaceutical Industries Ltd. - Key offerings
12.16 Theratechnologies Inc.
Exhibit 150: Theratechnologies Inc. - Overview
Exhibit 151: Theratechnologies Inc. - Product / Service
Exhibit 152: Theratechnologies Inc. - Key offerings
12.17 Viatris Inc.
Exhibit 153: Viatris Inc. - Overview
Exhibit 154: Viatris Inc. - Business segments
Exhibit 155: Viatris Inc. - Key offerings
Exhibit 156: Viatris Inc. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 157: Inclusions checklist
Exhibit 158: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 159: Currency conversion rates for US$
13.4 Research methodology
Exhibit 160: Research methodology
Exhibit 161: Validation techniques employed for market sizing
Exhibit 162: Information sources
13.5 List of abbreviations
Exhibit 163: List of abbreviations

Executive Summary

The analyst recognizes the following companies as the key players in the HIV treatment drugs market in Africa: Abbott Laboratories, AbbVie Inc., Alpha Pharma, Aspen Pharmacare Holdings Ltd., AstraZeneca Plc, Aurobindo Pharma Ltd., Avacare Health, Boehringer Ingelheim International GmbH, Cipla Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson, Merck and Co. Inc., SSI Diagnostica AS, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Theratechnologies Inc., and Viatris Inc.

Commenting on the report, one of the report's analysts said: 'The latest trend gaining momentum in the market is an increase in awareness by various organizations.'

According to the report, one of the major drivers for this market is the increasing prevalence of STDs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AbbVie Inc.
  • Alpha Pharma
  • Aspen Pharmacare Holdings Ltd.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Avacare Health
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Hetero Labs Ltd.
  • Johnson and Johnson
  • Merck and Co. Inc.
  • SSI Diagnostica AS
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Viatris Inc.

Related Topics

Related Reports

HIV Drugs Global Market Report 2024 - Product Image

HIV Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
North America HIV Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

North America HIV Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 124 Pages
  • North America
From
HIV Drugs: Global Strategic Business Report - Product Image

HIV Drugs: Global Strategic Business Report

  • Report
  • 164 Pages
  • Global
From
Global HIV Drugs Market - Product Image

Global HIV Drugs Market

  • Report
  • 158 Pages
  • Global
From
Global Hereditary Angioedema Therapeutics Market 2023-2027 - Product Image

Global Hereditary Angioedema Therapeutics Market 2023-2027

  • Report
  • 156 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.